Pulmonary Drugs Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Pulmonary Drugs Market to 2027 - Global Analysis and Forecasts by Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Others); Application (Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00003538 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Pulmonary drugs are used for the treatment of various conditions that affect the lungs. The pulmonary drugs covers medication for ambit of diseases that ranges from common cold to long-term cure diseases such as COPD and asthma. The pulmonary drugs are available in various dosage forms that include inhalers, oral tablets, liquids, injections and others.

MARKET DYNAMICS
The pulmonary drugs market is anticipated to grow in the forecast, owing to the factors such as increasing incidence of COPD and other respiratory diseases, rising number of population engaged in tobacco smoking, others. In addition, several initiatives undertaken by various government and non-government organizations for research and investment into pulmonary drugs therapeutics is expected to offer significant growth opportunities in the market during the forecast period.

MARKET SCOPE
The "Global Pulmonary drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of pulmonary drugs market with detailed market segmentation by drug class, application, distribution channel, and geography. The global pulmonary drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading pulmonary drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global pulmonary drugs market is segmented on the basis of drug class, application, distribution channel and geography. Based on drug class, the market is segmented as inhaled corticosteroids, long acting beta-2 agonists, antihistamines, vasodilators, short acting beta-2 agonists, and others. On the basis of application, the global pulmonary drugs market is segmented into, asthma & COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others. On the basis of distribution channel, the global pulmonary drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global pulmonary drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The pulmonary drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting pulmonary drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the pulmonary drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the pulmonary drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from pulmonary drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for pulmonary drugs market in the global market. Below mentioned is the list of few companies engaged in the pulmonary drugs market.
The report also includes the profiles of key pulmonary drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Sanofi
  • Mylan N.V.
  • Circassia
  • AstraZeneca Plc.
  • GlaxoSmithKline Plc
  • Mallinckrodt
  • CHIESI Farmaceutici SpA
  • ZAMBON COMPANY S.P.A.
  • Alaxia
  • Merck KGaA
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Pulmonary Drugs Market - By Drug Class
1.3.2 Pulmonary Drugs Market - By Application
1.3.3 Pulmonary Drugs Market - By Distribution Channel
1.3.4 Pulmonary Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. PULMONARY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PULMONARY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PULMONARY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. PULMONARY DRUGS - GLOBAL MARKET OVERVIEW
6.2. PULMONARY DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. PULMONARY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. INHALED CORTICOSTEROIDS
7.3.1. Overview
7.3.2. Inhaled Corticosteroids Market Forecast and Analysis
7.4. LONG ACTING BETA-2 AGONISTS
7.4.1. Overview
7.4.2. Long Acting Beta-2 Agonists Market Forecast and Analysis
7.5. ANTIHISTAMINES
7.5.1. Overview
7.5.2. Antihistamines Market Forecast and Analysis
7.6. VASODILATORS
7.6.1. Overview
7.6.2. Vasodilators Market Forecast and Analysis
7.7. SHORT ACTING BETA-2 AGONISTS
7.7.1. Overview
7.7.2. Short Acting Beta-2 Agonists Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. PULMONARY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ASTHMA & COPD
8.3.1. Overview
8.3.2. Asthma & COPD Market Forecast and Analysis
8.4. ALLERGIC RHINITIS
8.4.1. Overview
8.4.2. Allergic Rhinitis Market Forecast and Analysis
8.5. PULMONARY ARTERIAL HYPERTENSION
8.5.1. Overview
8.5.2. Pulmonary Arterial Hypertension Market Forecast and Analysis
8.6. CYSTIC FIBROSIS
8.6.1. Overview
8.6.2. Cystic Fibrosis Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. PULMONARY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. ONLINE PHARMACIES
9.5.1. Overview
9.5.2. Online Pharmacies Market Forecast and Analysis
10. PULMONARY DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Pulmonary Drugs Market Overview
10.1.2 North America Pulmonary Drugs Market Forecasts and Analysis
10.1.3 North America Pulmonary Drugs Market Forecasts and Analysis - By Drug Class
10.1.4 North America Pulmonary Drugs Market Forecasts and Analysis - By Application
10.1.5 North America Pulmonary Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Pulmonary Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Pulmonary Drugs Market
10.1.6.1.1 United States Pulmonary Drugs Market by Drug Class
10.1.6.1.2 United States Pulmonary Drugs Market by Application
10.1.6.1.3 United States Pulmonary Drugs Market by Distribution Channel
10.1.6.2 Canada Pulmonary Drugs Market
10.1.6.2.1 Canada Pulmonary Drugs Market by Drug Class
10.1.6.2.2 Canada Pulmonary Drugs Market by Application
10.1.6.2.3 Canada Pulmonary Drugs Market by Distribution Channel
10.1.6.3 Mexico Pulmonary Drugs Market
10.1.6.3.1 Mexico Pulmonary Drugs Market by Drug Class
10.1.6.3.2 Mexico Pulmonary Drugs Market by Application
10.1.6.3.3 Mexico Pulmonary Drugs Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Pulmonary Drugs Market Overview
10.2.2 Europe Pulmonary Drugs Market Forecasts and Analysis
10.2.3 Europe Pulmonary Drugs Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Pulmonary Drugs Market Forecasts and Analysis - By Application
10.2.5 Europe Pulmonary Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Pulmonary Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Pulmonary Drugs Market
10.2.6.1.1 Germany Pulmonary Drugs Market by Drug Class
10.2.6.1.2 Germany Pulmonary Drugs Market by Application
10.2.6.1.3 Germany Pulmonary Drugs Market by Distribution Channel
10.2.6.2 France Pulmonary Drugs Market
10.2.6.2.1 France Pulmonary Drugs Market by Drug Class
10.2.6.2.2 France Pulmonary Drugs Market by Application
10.2.6.2.3 France Pulmonary Drugs Market by Distribution Channel
10.2.6.3 Italy Pulmonary Drugs Market
10.2.6.3.1 Italy Pulmonary Drugs Market by Drug Class
10.2.6.3.2 Italy Pulmonary Drugs Market by Application
10.2.6.3.3 Italy Pulmonary Drugs Market by Distribution Channel
10.2.6.4 Spain Pulmonary Drugs Market
10.2.6.4.1 Spain Pulmonary Drugs Market by Drug Class
10.2.6.4.2 Spain Pulmonary Drugs Market by Application
10.2.6.4.3 Spain Pulmonary Drugs Market by Distribution Channel
10.2.6.5 United Kingdom Pulmonary Drugs Market
10.2.6.5.1 United Kingdom Pulmonary Drugs Market by Drug Class
10.2.6.5.2 United Kingdom Pulmonary Drugs Market by Application
10.2.6.5.3 United Kingdom Pulmonary Drugs Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Pulmonary Drugs Market Overview
10.3.2 Asia-Pacific Pulmonary Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Pulmonary Drugs Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Pulmonary Drugs Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Pulmonary Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Pulmonary Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Pulmonary Drugs Market
10.3.6.1.1 Australia Pulmonary Drugs Market by Drug Class
10.3.6.1.2 Australia Pulmonary Drugs Market by Application
10.3.6.1.3 Australia Pulmonary Drugs Market by Distribution Channel
10.3.6.2 China Pulmonary Drugs Market
10.3.6.2.1 China Pulmonary Drugs Market by Drug Class
10.3.6.2.2 China Pulmonary Drugs Market by Application
10.3.6.2.3 China Pulmonary Drugs Market by Distribution Channel
10.3.6.3 India Pulmonary Drugs Market
10.3.6.3.1 India Pulmonary Drugs Market by Drug Class
10.3.6.3.2 India Pulmonary Drugs Market by Application
10.3.6.3.3 India Pulmonary Drugs Market by Distribution Channel
10.3.6.4 Japan Pulmonary Drugs Market
10.3.6.4.1 Japan Pulmonary Drugs Market by Drug Class
10.3.6.4.2 Japan Pulmonary Drugs Market by Application
10.3.6.4.3 Japan Pulmonary Drugs Market by Distribution Channel
10.3.6.5 South Korea Pulmonary Drugs Market
10.3.6.5.1 South Korea Pulmonary Drugs Market by Drug Class
10.3.6.5.2 South Korea Pulmonary Drugs Market by Application
10.3.6.5.3 South Korea Pulmonary Drugs Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Pulmonary Drugs Market Overview
10.4.2 Middle East and Africa Pulmonary Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Pulmonary Drugs Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Pulmonary Drugs Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Pulmonary Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Pulmonary Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Pulmonary Drugs Market
10.4.6.1.1 South Africa Pulmonary Drugs Market by Drug Class
10.4.6.1.2 South Africa Pulmonary Drugs Market by Application
10.4.6.1.3 South Africa Pulmonary Drugs Market by Distribution Channel
10.4.6.2 Saudi Arabia Pulmonary Drugs Market
10.4.6.2.1 Saudi Arabia Pulmonary Drugs Market by Drug Class
10.4.6.2.2 Saudi Arabia Pulmonary Drugs Market by Application
10.4.6.2.3 Saudi Arabia Pulmonary Drugs Market by Distribution Channel
10.4.6.3 U.A.E Pulmonary Drugs Market
10.4.6.3.1 U.A.E Pulmonary Drugs Market by Drug Class
10.4.6.3.2 U.A.E Pulmonary Drugs Market by Application
10.4.6.3.3 U.A.E Pulmonary Drugs Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Pulmonary Drugs Market Overview
10.5.2 South and Central America Pulmonary Drugs Market Forecasts and Analysis
10.5.3 South and Central America Pulmonary Drugs Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Pulmonary Drugs Market Forecasts and Analysis - By Application
10.5.5 South and Central America Pulmonary Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Pulmonary Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Pulmonary Drugs Market
10.5.6.1.1 Brazil Pulmonary Drugs Market by Drug Class
10.5.6.1.2 Brazil Pulmonary Drugs Market by Application
10.5.6.1.3 Brazil Pulmonary Drugs Market by Distribution Channel
10.5.6.2 Argentina Pulmonary Drugs Market
10.5.6.2.1 Argentina Pulmonary Drugs Market by Drug Class
10.5.6.2.2 Argentina Pulmonary Drugs Market by Application
10.5.6.2.3 Argentina Pulmonary Drugs Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. PULMONARY DRUGS MARKET, KEY COMPANY PROFILES
12.1. SANOFI
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. MYLAN N.V.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. CIRCASSIA
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ASTRAZENECA PLC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MALLINCKRODT
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. CHIESI FARMACEUTICI SPA
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ZAMBON COMPANY S.P.A.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ALAXIA
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. MERCK KGAA
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Sanofi
2. Mylan N.V.
3. Circassia
4. AstraZeneca Plc.
5. GlaxoSmithKline Plc
6. Mallinckrodt
7. CHIESI Farmaceutici SpA
8. ZAMBON COMPANY S.P.A.
9. Alaxia
10. Merck KGaA